Acute myeloid leukemia
Conditions
Interventions
Experimental group :Decitabine +CAG+ venetoclax
Control Group:Cytarabine for 7 days and anthracyclines for 3 days
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: (1) Patients with acute myeloid leukemia (AML) diagnosed by bone marrow morphology and immunophenotyping (in line with WHO 2016 diagnostic criteria), including newly treated AML, secondary AML (MDS/MPN transformation AML and treatment-related AML) and relapsed AML; (2) Age <60 years old ;
Exclusion criteria
Exclusion criteria: (1) Other serious medical conditions that may limit participation in the trial (e.g., advanced infection, uncontrolled diabetes, severe cardiac insufficiency or angina, severe liver dysfunction, etc.); (2) Patients who are participating in other clinical trials; (3) Inability to understand or follow the research protocol; (4) Other conditions deemed unsuitable for inclusion by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete remission;Non-remission; | — |
Secondary
| Measure | Time frame |
|---|---|
| 1-year progression-free survival;1-year overall survival;Complete remission with incomplete recovery of blood routine indicators;Composite complete remission;Partial remission; | — |
Countries
China
Contacts
Public ContactYuping Gong
West China Hospital of Sichuan University
Outcome results
None listed